. 2024 Jan 24;10(1):e12446. doi: 10.1002/trc2.12446

TABLE 2.

CDR‐SB endpoint for ITT population

	AGB101	Placebo
Change from BL to week 78 in CDR‐SB
Mean (SD) Missing	0.90 (1.50) 25 (31%)	0.68 (1.36) 9 (35%)	0.95 (1.55) 16 (30%)	1.09 (2.02) 15 (18%)	1.13 (1.96) 10 (27%)	1.05 (2.11) 5 (11%)

AGB101

Placebo

Parameter

Overall

(N = 81)

ApoE‐4

Non‐carriers

(N = 26)

ApoE‐4

Carriers

(N = 54)

Overall

(N = 83)

ApoE‐4

Non‐carriers

(N = 37)

ApoE‐4

Carriers

(N = 45)

Change from BL to week 78 in CDR‐SB

Mean (SD)

Missing

0.90 (1.50)

25 (31%)

0.68 (1.36)

9 (35%)

0.95 (1.55)

16 (30%)

1.09 (2.02)

15 (18%)

1.13 (1.96)

10 (27%)

1.05 (2.11)

5 (11%)

Abbreviations: Apo‐E, apolipoprotein E; BL, baseline; CDR‐SB, Clinical Dementia Rating Scale; ITT, intention‐to‐treat.